
Reset all filters
01 7Bevespi
02 6Breztri
03 4Cortiment
04 1Eohilia
05 2Lonhala Magnair
06 11Pulmicort
07 6Seebri Breezhaler
08 7Symbicort
09 5Uceris
10 1Uceris/Cortiment
11 6Ultibro Breezhaler
12 3Ultibro Group
Budesonide, Glycopyrronium, Formoterol Fumarate
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 0
2019 Revenue in Millions : 213
Growth (%) : -100
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 48
2019 Revenue in Millions : 42
Growth (%) : 14
Budesonide, Glycopyrronium, Formoterol Fumarate
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 996
2019 Revenue in Millions : 1,466
Growth (%) : -32
Budesonide, Glycopyrronium, Formoterol Fumarate
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 28
2019 Revenue in Millions : 2
Growth (%) : 1,300
Budesonide, Glycopyrronium, Formoterol Fumarate
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 2,721
2019 Revenue in Millions : 2,495
Growth (%) : 9
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 22
2019 Revenue in Millions : 17
Growth (%) : 28
Budesonide, Glycopyrronium, Formoterol Fumarate
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 6
2019 Revenue in Millions : 11
Growth (%) : -48
Budesonide, Glycopyrronium, Formoterol Fumarate
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 8
2019 Revenue in Millions : 5
Growth (%) : 70
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 623
2019 Revenue in Millions : 630
Growth (%) : -1
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2021 Revenue in Millions : 54
2020 Revenue in Millions : 48
Growth (%) : 13